Statement: less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.
Primary_evidence: Outcome Measurement:    Percentage of Participants With Progressive Disease at Week 12 in Cohort 1   The percentage of participants with progressive disease (PD) 12 weeks after randomization was measured. Per Response Evaluation Criteria In Solid Tumors (RECIST), a response of PD is defined as a >=20% increase in target lesions. Participants were also classified as having PD if their response at Week 12 was unknown or missing. Response was determined by an independent radiologist and by an investigator.   Time frame: Week 12 Results 1:    Arm/Group Title: Cohort 1: Lapatinib 1500 mg   Arm/Group Description: Lapatinib 1500 milligrams (mg) administered orally once a day   Overall Number of Participants Analyzed: 72   Measure Type: Number   Unit of Measure: percentage of participants  Independently Evaluated: 38.9   Investigator Evaluated: 43.1 Results 2:    Arm/Group Title: Cohort 1: Lapatinib 1000 mg/Pazopanib 400 mg   Arm/Group Description: Lapatinib 1000 mg and Pazopanib 400 mg administered orally once a day   Overall Number of Participants Analyzed: 69   Measure Type: Number   Unit of Measure: percentage of participants  Independently Evaluated: 36.2   Investigator Evaluated: 37.7